Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate‐to‐severe atopic dermatitis in adults: A multicentre real‐world study

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to the privacy or ethical restrictions.